tbuckley/cabot-search huggingface dataset:
COMPLEX ROBOTICALLY-ASSISTED PERCUTANEOUS CORONARY INTERVENTIONS: REASONS FOR PARTIAL MANUAL ASSISTANCE OR MANUAL CONVERSION
Authors: Jonathan Harrison, Jesse Naghi, Lawrence Ang, John Bahadorani, Arturo Dominguez, Song Cui, Omid Behnamfar, Mitul Patel, Ryan Reeves, Ehtisham Mahmud
Journal: Journal of the American College of Cardiology (2016)
THU0218 Diabetes Effects on Incidence of Radiographic Knee OA and Its Structural Progression: A Longitudinal Analysis of the Osteoarthritis Initiative Data: Table 1.
Authors: I. Shirinsky, V. Shirinsky
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Multiple epidemiological and experimental data indicate that diabetes may be one of osteoarthritis risk factors. In spite of this, there is a lack of data on whether diabetes is an independent predictor of knee OA incidence and progression. <h3>Objectives</h3> To assess influence of diabetes on incidence of radiographic knee OA and to evaluate diabetes effects on OA structural progression using radiological and MRI measures. <h3>Methods</h3> For the current study we used longitudinal data obtained from the Osteoarthritis Initiative (OAI) progression (n=1390) and incidence (n=3284) subcohorts, which are publically available at http://oai.epi-ucsf.org. Incident knee OA was defined either as the occurrence of (a) new or enlarging definite osteophyte (OSP) or (b) new combination of a definite OSP and joint space narrowing (JSN). Incident OSP and JSN were defined as a development of OARSI grade &gt;0. Radigraphic outcomes were assessed at baseline and years 1,2,3, and 4. For the analysis of diabetes effects on OA progression we assessed changes in bone marrow edema (BME) volume (baseline, year 1) and cartilage volume (baseline, years 1,2), each measured at six separate knee anatomical locations using MRI. The information on previously diagnosed diabetes was collected from the self-reported Charlson Comorbidity Index. Cox proportional hazards models and generalized estimating equations (GEE) were used to evaluate diabetes effects on dichotomized and continuous outcomes, respectively. We used both univariate and multivariate models, the latter were adjusted for demographic characteristics, prior knee surgery, Physical Activity Scale for the Elderly, body mass index (BMI), and family history of knee OA. <h3>Results</h3> On baseline, 151 (10.9%) patients in progression subcohort and 210 (6.4%) patients in incidence subcohort reported diabetes. Diabetes effects on radiographic knee OA, individual radiographic OA feature incidence, cartilage volume and BME volume were analyzed in 4794, 1130, 600, and 160 knees, respectively. In univariate analyses diabetes was associated with increased risk of medial JSN and medial femur osteophyte incidence. Correction for BMI and other predictor variables reversed the effect and diabetes became associated with decreased risk of incident knee OA, medial and lateral JSN (Table). In both univariate and multivariate analyses diabetes had no effect on knee OA progression assessed by cartilage volume and BME volume changes over time. <h3>Conclusions</h3> Diabetes is independently associated with decreased incidence of radiographic knee OA, while having no influence on its structural progression. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2791
Abstract 254: A HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis
Authors: Zheng Li, Qian Zhang, Jian-Hua Mao, Anja Weise, Kristin Mrasek, Xueyu Fan, Xifeng Zhang, Thomas Liehr, Karen H. Lu, Allan Balmain, Wei-Wen Cai
Journal: Cancer Research (2010)

Abstract There is a gap between the initial formation of cells carrying radiation-induced genetic damage and their contribution to cancer development. Herein we reveal a previously uncharacterized gene FATS through a genome-wide approach and demonstrate its essential role in regulating the abundance of p21 in surveillance of genome integrity. A large exon coding the NH2-terminal domain of FATS, deleted in spontaneous mouse lymphomas, is much more frequently deleted in radiation-induced mouse lymphomas. Its human counterpart is a fragile site gene at a previously identified loss of heterozygosity (LOH) site. FATS is essential for maintaining steady-state level of p21 protein and sustaining DNA damage checkpoint. Furthermore, the NH2-terminal FATS physically interacts with HDAC1 to enhance the acetylation of endogenous p21, leading to the stabilization of p21. Our results reveal a molecular linkage between p21 abundance and radiation-induced carcinogenesis. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 254.
Abstract 45: Accurate total and allele-specific copy number measurements in mosaic tumors
Authors: Bo Curry, Nick Sampas, Paige Anderson, Brian Peter
Journal: Cancer Research (2011)

Abstract For the characterization of genomic copy number changes that occur in the development and progression of cancer, oligonucleotide array comparative genomic hybridization (aCGH) offers high-resolution and precise determination of chromosomal copy number and genome-wide aberrations. We recently reported a new method for making simultaneous measurements of single nucleotide polymorphisms (SNPs) and copy number alterations in the same microarray assay. The combined assay can detect copy-number neutral events, such as acquired loss of heterozygosity (LOH), as well as allelic imbalance in and around amplified regions. Previously reported algorithms for analyzing Agilent CGH+SNP data were able to genotype primarily diploid samples and to detect regions of constitutional LOH. However, tumor heterogeneity, aneuploidy and variable sample quality create significant challenges for both solid and liquid tumors. Our earlier methods were often unable to cope with the high levels of aneuploidy sometimes found in solid tumors, or with admixtures of normal cells and aberrant cells. We now describe new computational methods which can determine total copy number, aneuploid fraction, and allele-specific copy number in many aneuploid tumor samples, even when mixed with up to 80% normal tissue. We report results from genomic DNA isolated from a cancer cell line, a blood sample, and a solid tumor. Each of these sample types presents novel challenges. The cell line we studied, though largely monoclonal, is highly aneuploid. The blood DNA is of high quality, but the fraction of tumor cells in the sample is low. The solid tumor DNA is of relatively low quality, and composed of multiple aberrant clones. We were able to determine the aneuploid fraction of the tumors, and to measure copy number variation in samples with as little as 20% tumor cell content. In addition to detecting copy-neutral LOH regions, we also measured allele-specific copy number, both of the aberrant clone and of admixed normal cells. The new analysis methods allow the extension of the extra allelic information available from the CGH+SNP assay to cancer samples. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 45. doi:10.1158/1538-7445.AM2011-45
T-cell transcriptome analysis points up a thymic disorder in idiopathic nephrotic syndrome
Authors: Hicham Mansour, Lydie L Cheval, Jean-Marc Elalouf, Jean-Christophe Aude, Maria-Alexandra Alyanakian, Béatrice Mougenot, Alain L Doucet, Georges Deschênes, Baatrice Mougenot, Georges Deschanes
Journal: Kidney International (2005)
PREVALENCE AND MANAGEMENT OF PATIENT-REPORTED SYMPTOMS ON STATIN THERAPY: INSIGHTS FROM THE PATIENT AND PROVIDER ASSESSMENT OF LIPID MANAGEMENT (PALM) REGISTRY
Authors: Ann Marie Navar Boggan, Eric Peterson, Shuang Li, Peter Wilson, Anne Goldberg, Salim Virani, Jennifer Robinson, Veronique Roger, Joseph J. Elassal, L. Veronica Lee, Michael Pencina, Tracy Wang
Journal: Journal of the American College of Cardiology (2016)
Royal College urges CCGs to reconsider plans to restrict surgery
Authors: Gareth Iacobucci
Journal: BMJ (2016)

The Royal College of Surgeons (RCS) has written to six Clinical Commissioning Groups (CCGs) in Birmingham to express its concern about their plans to restrict access to surgery.

The commissioning groups are consulting on plans to place thresholds on several planned surgical procedures—including hip and knee replacements and hernia repair—on the basis that they are lower clinical value.1

But in an open letter published on 5 April,2 the RCS urged the groups, which commission care for six million people in the region, to reconsider their position.

The college said that it was particularly concerned that guidance from the National Institute for Health and Care Excellence (NICE), …
BARIATRIC ARTERIAL EMBOLIZATION AS TREATMENT FOR OBESITY: MECHANISMS USING HIGHLY CALIBRATED 50 MICRON EMBOLIC BEADS
Authors: Dara L. Kraitchman, Charles Hu, Robert Anders, Timothy Moran, Jaskaran Singh, Paul DiCamillo, Eun Shin, Mao Hai-Quan, Tza-Huei Wang, Arepally Aravind, Clifford Weiss
Journal: Journal of the American College of Cardiology (2015)
Comparison of Single Time-Point [111-In] Pentetreotide SPECT/CT With Dual Time-Point Imaging of Neuroendocrine Tumors
Authors: Ka Kit Wong, Elizabeth A. Wynn, Jamie Myles, Robert J. Ackermann, Kirk A. Frey, Anca M. Avram
Journal: Clinical Nuclear Medicine (2010)

Purpose: To determine whether single time-point single-photon emission computed tomography—computed tomography (SPECT/CT) somatostatin receptor imaging can replace traditional dual time-point planar and SPECT somatostatin receptor scintigraphy for evaluation of neuroendocrine tumors. Materials and Methods: Twenty-four patients (9 males, 15 females; mean age: 56 years; range: 14–82 years) underwent [111-In] pentetreotide scintigraphy, with planar whole-body images acquired at 24 and 48 hours after injection and abdominal SPECT/CT at 24 hours postinjection. Two blinded readers independently interpreted each study, using single time-point (24 hours planar and SPECT/CT) and separately using dual time-point (24- and 48-hours planar, and 24-hour SPECT without CT) image information. Consensus interpretations were compared with surgical pathology, or clinical and radiologic follow-up for at least 12 months. Results: Interobserver agreement was excellent (κ = 0.86) for single time-point imaging, and good (κ = 0.56) with dual time-point imaging. After consensus review, single time-point imaging identified pathologic lesions in 11 of 12 subjects with diagnosis of NET at follow-up, and in 0 of 12 subjects without NET (sensitivity 92%; specificity 100%). Dual time-point imaging performed similarly, but missed an additional NET case (sensitivity 83%; specificity 100%). After review of SPECT/CT, the readers considered that additional 48 hours imaging was not necessary in the majority of cases, indicating high degree of confidence with the single time-point imaging. Conclusion: [111-In] pentetreotide SPECT/CT imaging at 24 hours identifies pathologic disease sites and distinguishes physiologic activity equally well compared to traditional strategies using 2 imaging days. Routine use of SPECT/CT will allow single time-point imaging without loss of diagnostic accuracy, enhancing patient convenience, and clinical throughput.
DIAGNOSTIC YIELD OF FOCUSED ENDOSCOPIC ULTRASOUND EXAMINATION OF THE BILIARY TREE IN A TERTIARY REFERRAL CENTRE
Authors: A Alakkari, R Leen, N Breslin, B Ryan
Journal: Gut (2013)

<h3>Introduction</h3> Endoscopic ultrasound (EUS) provides detailed examination of bile ducts where other imaging modalities have failed to identify an abnormality or when dilated ducts have been identified on imaging, but no cause found. <h3>Aims/Background</h3> This audit reviews the results of focused EUS of the biliary tree performed in Tallaght hospital over a 16 month period. <h3>Method</h3> Data was collected on patients who underwent EUS examinations of the biliary tree between October 2011 and February 2012. Patients with known pathology prior to EUS, like pancreatic mass or bile duct stone identified on prior imaging were excluded. <h3>Results</h3> Of a total of 477 EUSs, 126 were focused diagnostic procedures for possible biliary pathology, 87 (69%) female and 39 (31%) male. Median age was 57.5 years. Indications were: 47 (37%) for abnormal bile ducts on imaging, 41 (32%) abdominal pain, 28 (22%) query gallstones, and 7 (9%) jaundice/ abnormal liver function tests (LFTs). Patients were age stratified into group A (&lt;60 years) and group B (&gt;60 years). Chi–square test was used for statistical analysis. On EUS, Group A compared to group B had less dilated bile ducts (43% vs 61%, p 0.056), dilated pancreatic ducts (12% vs 17%, p 0.045) and less pathology (28% vs 51%, p 0.001). Patients with abnormal LFTs had more pathology compared to normal LFTs (48% vs 21.6%, p 0.002). Following age stratification, this was only significant in group A (38% vs 9%, p 0.004). Therefore, abnormal LFTs were a predictor of pathology in younger patients but not older ones. More pathology was diagnosed in patients with dilated bile ducts on EUS who did not have previous cholecystectomy, regardless of age (19% vs 76%, p&lt;0.001). Duodenal diverticulum was diagnosed in 4 patients in group B. This is likely under diagnosed due to diagnostic limitations of EUS. <h3>Conclusion</h3> EUS is high yield in young patients with abnormal LFTs and older patients regardless of LFTs when their presentation suggests biliary tree disease. The corollary is that young patients with normal LFTs are unlikely to have pathology. Investigators should be vigilant of periampullary diverticuli (Lemmel9s syndrome) in older patients with unexplained bile duct dilatation.
THE PREDICTORS AND CLINICAL IMPACT OF FAILURE OF TRANSRADIAL APPROACH FOR PRIMARY PERCUTANEOUS CORONARY INTERVENTION IN STEMI PATIENTS IN THE SINGLE-CENTER REGISTRY
Authors: Kazunori Horie, Yusuke Toki, Takashi Matsumoto, Tsuyoshi Isawa, Norio Tada, Taku Honda, Kaname Takizawa, Tatsushi Otomo, Naoto Inoue
Journal: Journal of the American College of Cardiology (2016)
Camptothecins Resurface as Promising Drugs
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Camptothecins Resurface as Promising Drugs Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 15, 3 August 1994, Pages 1118–1120, https://doi.org/10.1093/jnci/86.15.1118 Published: 03 August 1994
Abstract 620: Chemoprevention of hydroxybutyl(butyl)nitrosamine (OH-BBN)-induced mouse urinary bladder cancer by the kava chalcone flavokawain A
Authors: Xia Xu, Zhongbo Liu, Shuman Liu, Xuesen Li, Xiaolin Zi
Journal: Cancer Research (2012)

Abstract About 75% of human bladder cancers are associated with cigarette smoking or exposure to industrial carcinogens. Kava roots have been traditionally used to prepare beverage and herb medicine in the South Pacific Island nations (Fiji, Vanutu, Samoa, etc.) for thousands of years. Recently, an epidemiological study has linked high kava consumption to lower incidences of cancers, including lung and bladder cancers, despite the presence of many smokers in the populations of the South Pacific Islands. We therefore examined the potential of flavokawain A, a predominant chalcone isolated from the kava plant for prevention of mouse urinary bladder cancer induced by the organ-specific and tobacco-smoking related nitrosamine OH-BBN. B6D2F1 mice at 8 weeks of age were gavaged 7.5 mg OH-BBN once per week for 12 weeks. In the standard prevention protocol, 0.1% FKA or vehicle food was administered as a dietary supplement to each group of mice beginning 1 week before the first OH-BBN administration and ending 32 weeks after the initial OH-BBN treatment. Dietary feeding of OH-BBN treated mice with 0.1% flavokawain A in the mouse diet decreased bladder wet weight by about 57% (Bladder weights for control versus flavokawain A were 74.18 ± 16.7 versus 32 ± 1.5 mg; P&amp;lt;0.01). In the standard promotion protocol, 0.1% FKA or vehicle food was given 1 week after the final OH-BBN administration for 19 weeks. Flavokawain A also significant reduced the bladder wet weight by about 27% (Bladder weights for control versus flavokawain A were 89.4 ± 23.4 versus 65.5 ± 10.6 mg; p&amp;lt;0.05). To increase the incidence of palpable OH-BBN induced bladder tumors, we extended 7.5mg OH-BBN treatment once per week for one more week up to a total of 13 weeks. In this modified promotion protocol, the percentage of palpable tumors in control group has reached to about 53%, which is similar to that reported by published literatures. Dietary feeding of 0.6% flavokawain A significantly decrease bladder wet weight by 73% (Bladder weights for control versus flavokawain A were 314.9 ± 106.7 versus 87.3 ± 15.2 mg, p=0.0265). In addition, we showed that flavokawain A induced activities of phase II enzyme (i.e. glutathione S-transferase and quinone reductase) in different organs (bladder, liver, prostate, etc.) of mice. Taken together, these results suggest that flavokawain A deserves further investigation for bladder cancer chemoprevention by targeting smoking or carcinogens exposed populations. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 620. doi:1538-7445.AM2012-620
AB0536 Renal Biopsy in Patients with Systemic Lupus Erythematosus and Proteinuria Less than 0.5 G/24Hrs: Table 1
Authors: M. Ricse, J. Narváez, G. Albert, P. Estrada, E. Armengol, C. Giménez, A. Roset, E. De Lama, J. Torras, J. Rodríguez, F. Mitjavila, J.M. Nolla
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The currently indications for a first renal biopsy in patients with systemic lupus erythematosus (SLE) are the presence of a confirmed 24 hours urinary proteins ≥0.5 g, an active urinary sediment (microhematuria/buffy/casts) or an unexplained deterioration of renal function. The performance of renal biopsies in patients with proteinuria below 0.5 g/day and inactive sediment or with minimal alterations, is still in discussion. However, current knowledges of the existence of silent lupus nephritis have reopened the debate on the need to perform biopsies with the purpose of evidencing minimal renal disease, in SLE and basic activity disease. <h3>Objectives</h3> To review the histological findings in patients with SLE and urinary proteins lower than 0.5 g in 24 Hours. <h3>Methods</h3> We have included 243 patients with SLE, all attended in a Tertiary University Hospital without pediatric population assigned, between 1980 and 2013. They have been recorded in a specific database (ACHILLES record). Were selected patients without renal failure who underwent renal biopsy because they presented proteinuria &lt;0.5 g/24 hours of recent onset (present in 2 consecutive samples) with active urinary sediment. <h3>Results</h3> Six patients were identified, all with SLE immunologically active. The biopsy was performed for presenting, along with proteinuria, an active urinary sediment with pyuria and/or intermittent or persistent microscopic hematuria, but with evidence of more than 80% dysmorphic RBCs suggesting glomerular origin. In 5 of the 6 patients, renal biopsy demonstrated the existence of lupus nephritis. In the remaining patient, biopsy identified the presence of thrombotic microangiopathy as a result of a secondary antiphospholipid syndrome. The main clinical and histological data are showed in the following table. <h3>Conclusions</h3> In patients with active SLE, histological findings compatible with lupus nephritis can be seen even with less than 0.5 g/24 hours urinary proteins (including the presence of severe histological classes in a high percentage of patients). <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5662
The Emerging Threat of Untreatable Gonococcal Infection
Authors: Sarah Duncan, Christopher J. Duncan
Journal: New England Journal of Medicine (2012)

To the Editor: In their summary of the global threat of antibiotic-resistant Neisseria gonorrhoeae, Bolan et al. (Feb. 9 issue)1 state that “in patients who are allergic to cephalosporins, the only option is 2 g of azithromycin orally.” However, the aminoglycoside spectinomycin (unavailable in the United States since 2006) has proven efficacy against genital gonococcal infection2 and is recommended for patients in the United Kingdom who are allergic to penicillin.3 Since most gonococcal isolates remain susceptible to spectinomycin, it represents a viable option for cephalosporin-resistant genital gonorrhea,2,3 although ongoing uncertainty regarding manufacturing and supply may compromise its future usefulness. . . .